APA (7th ed.) Citation

Markert, C., Burhenne, J., Weiß, J., Mikus, G., & Haefeli, W. E. (2014). CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Clinical pharmacology & therapeutics, 95(3), . https://doi.org/10.1038/clpt.2013.188

Chicago Style (17th ed.) Citation

Markert, Christoph, Jürgen Burhenne, Johanna Weiß, Gerd Mikus, and Walter E. Haefeli. "CYP2C9 Polymorphism Is Not a Major Determinant of Bosentan Exposure in Healthy Volunteers." Clinical Pharmacology & Therapeutics 95, no. 3 (2014). https://doi.org/10.1038/clpt.2013.188.

MLA (9th ed.) Citation

Markert, Christoph, et al. "CYP2C9 Polymorphism Is Not a Major Determinant of Bosentan Exposure in Healthy Volunteers." Clinical Pharmacology & Therapeutics, vol. 95, no. 3, 2014, https://doi.org/10.1038/clpt.2013.188.